Home | Investor Relations
Stock Quote (NASDAQ: NSTG)
+ 0.86
Day High:
Day Low:
4:00 PM ET on Jan 29, 2015
Delayed at least 20 minutes.
Provided by eSignal.

Search Investor Relations

Investor Relations

NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter® Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in hundreds of peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology has now been applied to diagnostic use. The Prosigna® Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer.

Key Publication

ARTICLEAug 01, 2013
Comparison of PAM50 Risk of Recurrence Score With Oncotype DX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine Therapy
Dowsett M. et al., Journal of Clinical Oncology August 1, 2013 vol. 31 no. 22 2783-2790

View all »Upcoming Events

WEBCASTFeb 11, 2015 at 8:25 AM ET
2015 Leerink Global Healthcare Conference

View all »Events & Webcasts

WEBCASTFeb 11, 2015 at 8:25 AM ET
2015 Leerink Global Healthcare Conference
WEBCASTJan 14, 2015 at 4:00 PM PT
J.P. Morgan 33rd Annual Healthcare Conference
PDF View Presentation  3.4 MB   Add to Briefcase
WEBCASTNov 20, 2014 at 11:00 AM ET
Canaccord Genuity Medical Technology and Diagnostics Forum